Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05895929 · ClinicalTrials.gov registry record · Early Phase 1
The Role of IL5 in Epithelial Cell Integrity
A Early Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps and Chronic Rhinosinusitis (Diagnosis), sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT05895929 is a Early Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps and Chronic Rhinosinusitis (Diagnosis) that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 8 participants, below the 142-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05895929, a Early Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps and Chronic Rhinosinusitis (Diagnosis), is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells
Conditions Studied
Interventions
- DRUG Mepolizumab
Study Locations (2)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05895929
The ClinicalTrials.gov registry entry for NCT05895929 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (94% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Mepolizumab is the first listed.
NCT05895929 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05895929 about?
NCT05895929 is a clinical study titled "The Role of IL5 in Epithelial Cell Integrity". The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To ...
What is the current status of trial NCT05895929?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2023-09-05. Estimated completion is 2026-06.
What conditions does trial NCT05895929 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis).
What interventions are being tested in trial NCT05895929?
The interventions under investigation include: Mepolizumab (DRUG).
Who is sponsoring clinical trial NCT05895929?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05895929 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
RECRUITING · Phase 2
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
-
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
RECRUITING
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
Explore more on PlainTrial
Chronic Rhinosinusitis With Nasal Polyps
All registered trials for this condition
Chronic Rhinosinusitis (Diagnosis)
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.